Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi and Janssen Pharmaceuticals today announced a licensing agreement to develop and market an investigational vaccine against extraintestinal pathogenic…
Despite nearly 40 years of clinical trials, there is still no licensed vaccine against extraintestinal pathogenic Escherichia coli. ExPEC causes an estimated…
Sanofi and Johnson & Johnson today announced that they have decided to discontinue the Phase 3 E.mbrace study of ExPEC9V based on the recommendation of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Sanofi entered an October 3, 2023 agreement with Janssen (Johnson & Johnson) to co-develop and commercialize ExPEC9V (VAC52416), a Phase 3 9-valent bioconjugate vaccine against invasive extraintestinal pathogenic E. coli disease (IED). Sanofi paid $175M upfront plus undisclosed development/commercial milestones, with a US/EU4/UK profit share and tiered royalties + sales milestones to Janssen in ex-major markets; the deal closed November 9, 2023. On February 13, 2025, the partners DISCONTINUED the pivotal Phase 3 E.mbrace study after an independent data monitoring committee found ExPEC9V did not demonstrate sufficient efficacy versus placebo in preventing IED (no safety concerns identified). Sanofi recorded a ~$250M impairment in Q4 2024 covering the upfront and development milestones paid to Janssen, reducing FY2024 IFRS EPS by EUR 0.15 while maintaining 2025 guidance. The licensed lead asset has effectively failed; the original commercialization thesis no longer holds. Upfront-only disclosed total was $175M; included under the Top-25 buyer rule.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (this deal) | 2023 | $175M | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2023 deals · Sanofi SA deals · Infectious Disease deals